These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2312783)

  • 1. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function.
    Schoerlin MP; Horber FF; Frey FJ; Mayersohn M
    J Clin Pharmacol; 1990 Mar; 30(3):272-84. PubMed ID: 2312783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.
    Schoerlin MP; Mayersohn M; Korn A; Eggers H
    Clin Pharmacol Ther; 1987 Oct; 42(4):395-404. PubMed ID: 3665338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function.
    Stoeckel K; Pfefen JP; Mayersohn M; Schoerlin MP; Andressen C; Ohnhaus EE; Frey F; Guentert TW
    Acta Psychiatr Scand Suppl; 1990; 360():94-7. PubMed ID: 2248088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    Clin Pharmacol Ther; 1991 Jan; 49(1):32-8. PubMed ID: 1988238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.
    Mayersohn M; Guentert TW
    Clin Pharmacokinet; 1995 Nov; 29(5):292-332. PubMed ID: 8582117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
    Holford NH; Guentert TW; Dingemanse J; Banken L
    Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA; Raaflaub J; Kettler R
    Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163).
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    J Neural Transm Suppl; 1988; 26():115-21. PubMed ID: 3283288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moclobemide excretion in human breast milk.
    Pons G; Schoerlin MP; Tam YK; Moran C; Pfefen JP; Francoual C; Pedarriosse AM; Chavinie J; Olive G
    Br J Clin Pharmacol; 1990 Jan; 29(1):27-31. PubMed ID: 2297459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.
    Raaflaub J; Haefelfinger P; Trautmann KH
    Arzneimittelforschung; 1984; 34(1):80-2. PubMed ID: 6538424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cytochrome P450 2D6 in the metabolism of moclobemide.
    Härtter S; Dingemanse J; Baier D; Ziegler G; Hiemke C
    Eur Neuropsychopharmacol; 1996 Aug; 6(3):225-30. PubMed ID: 8880082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days.
    Guentert TW; Tucker G; Korn A; Pfefen JP; Haefelfinger P; Schoerlin MP
    Acta Psychiatr Scand Suppl; 1990; 360():91-3. PubMed ID: 2248087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species-specific biotransformation of moclobemide: a comparative study in rats and humans.
    Schoerlin MP; Da Prada M
    Acta Psychiatr Scand Suppl; 1990; 360():108-10. PubMed ID: 2248061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
    Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine.
    Schoerlin MP; Blouin RA; Pfefen JP; Guentert TW
    Acta Psychiatr Scand Suppl; 1990; 360():98-100. PubMed ID: 2248089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.